ARIEL 2 enrolled platinum-sensitive EOC patients, assigned to one of three HR deficiency categories assessed on the most recent collected tumor sample: BRCA1/2 mutated, BRCA wild-type (BRCAwt) with LOH high, and BRCAwt with LOH low, respectively [32,34]. The gene discussed is BRCA1; the disease is neoplasm.